Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MRD Clear all
Active, not recruiting Phase 2 Interventional Results available

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

NCT01059786
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Pentostatin, Rituximab, Bendamustine, Acetaminophen, Diphenhydramine, Epinephrine, Antihistamines, Corticosteroids, Bronchodilators, Intravenous (IV) Saline
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 3, 2026, 3:20 AM EDT
Recruiting Phase 2 Interventional

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT06054776
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Glofitamab, Multigated Acquisition Scan, Obinutuzumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 3, 2026, 3:20 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

NCT05434689
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Iberdomide, Daratumumab, Dexamethasone, Carfilzomib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Birmingham, Alabama • Columbus, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 3, 2026, 3:20 AM EDT
Completed Phase 2 Interventional Results available

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

NCT03788291
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Acalabrutinib, Rituximab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Sep 3, 2026, 3:20 AM EDT
Active, not recruiting Phase 2 Interventional

Cevostamab Following CAR T Cell Therapy for RRMM

NCT05801939
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Cevostamab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 3, 2026, 3:20 AM EDT
Not yet recruiting Phase 3 Interventional

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 3, 2026, 3:20 AM EDT
Completed Phase 1 Interventional

Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention

NCT02423915
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Total Body Radiation, Fucosylated Regulatory T Cells, Cord Blood Infusions, Mycophenolate mofetil, Sirolimus, Bone Marrow Aspiration, G-CSF, Non-Fucosylated Regulatory T Cells
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 3, 2026, 3:20 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

NCT04521231
View directory record Official record
Conditions
B Cell Precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
13
States / cities
Clovis, California • Duarte, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 3, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Results available

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017
View directory record Official record
Conditions
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions
ELI-002 2P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 3, 2026, 3:20 AM EDT
Recruiting Phase 2 Interventional

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

NCT06144606
View directory record Official record
Conditions
B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia
Interventions
Tecartus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 3, 2026, 3:20 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

NCT02769065
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 3, 2026, 3:20 AM EDT
Recruiting Phase 1 Interventional

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

NCT01555892
View directory record Official record
Conditions
Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease, Lymphoma
Interventions
EBV-specific T cells: A, EBV-specific T cells: B
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 3, 2026, 3:20 AM EDT
Recruiting Phase 2 Interventional

Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)

NCT07222579
View directory record Official record
Conditions
CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
Interventions
Subcutaneous Blinatumomab
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 3:20 AM EDT
Active, not recruiting Not applicable Interventional

Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors

NCT00959140
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
CD3+ T cell depletion
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 3, 2026, 3:20 AM EDT
Recruiting No phase listed Observational

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

NCT07211178
View directory record Official record
Conditions
Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer, Early Stage Breast Cancer
Interventions
There are no interventions in this observational study.
Other
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years to 99 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
14
States / cities
Birmingham, Alabama • Whittier, California • Weston, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 3, 2026, 3:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

NCT06284486
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Venetoclax, Revumenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 3:20 AM EDT
Terminated Phase 1 Interventional

Study of GDX012 in Patients With MRD Positive AML

NCT05001451
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
GDX012 Suspension for IV Infusion
Biological
Lead sponsor
GammaDelta Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 3, 2026, 3:20 AM EDT
Recruiting No phase listed Observational

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444
View directory record Official record
Conditions
Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma
Interventions
Guardant Reveal
Diagnostic Test
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
33
States / cities
Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 3, 2026, 3:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

NCT02748694
View directory record Official record
Conditions
Healthy Volunteers, Schizophrenia
Interventions
TAK-041, TAK-041 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Sep 3, 2026, 3:20 AM EDT
Recruiting Phase 2 Interventional

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

NCT06511882
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Decitabine, Venetoclax
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 3, 2026, 3:20 AM EDT
Active, not recruiting Phase 2 Interventional Results available

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

NCT04284787
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
Interventions
Azacitidine, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab, Venetoclax
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
29
States / cities
Greenwich, Connecticut • Hartford, Connecticut • New Haven, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 3, 2026, 3:20 AM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

NCT00072358
View directory record Official record
Conditions
Neuroblastoma
Interventions
anti-GD2 murine IgG3 monoclonal antibody 3F8
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 3, 2026, 3:20 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

NCT03298412
View directory record Official record
Conditions
High-risk Diffuse Large B-cell Lymphoma
Interventions
Blinatumomab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Maywood, Illinois • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 3, 2026, 3:20 AM EDT
Completed Not applicable Interventional Results available

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

NCT02100930
View directory record Official record
Conditions
Neuroblastoma
Interventions
Anti-GD2 3F8 Monoclonal Antibody, GM-CSF (granulocyte-macrophage colony-stimulating factor), oral isotretinoin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 3, 2026, 3:20 AM EDT